Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 7;11:3383. doi: 10.1038/s41467-020-17205-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a BALB/c mice (10- to 12-week-old males) were treated daily with JQ1 (50 mg/kg) or vehicle (DMSO/10% ß-cyclo dextrin 1:10) starting on the day of aristolochic acid (AA) injection (3 mg/kg BW) or day 7 after AA injection. Mice were sacrificed on day 21 after AA injection. b Serum creatinine (mg/dL) trajectories of vehicle and JQ1 treated mice from day 0 until day 21 after AA (mean ± SD). vehicle: n = 7; JQ1 d0: n = 6; JQ1 d7: n = 8 biologically independent samples. c Survival curves after AA injection: 100% survial in vehicle and JQ1 d7 group, 67% survival in mice treated with JQ1 from day 0 until day 21 after AA injection. d Representative Ki67-1/Acta2-immunostained AAN kidneys treated with vehicle or JQ1 d0 or JQ1 d7. e Quantification of α-SMA+ (Acta2) surface area. Percentage of Ki67+ cells (Ki67+ cells/total number of cells (DAPI) per hpf). vehicle: n = 7 (60 hpf); JQ1 d0: n = 4 (33 hpf); JQ1 d7: n = 8 (64 hpf) at least 8 hpf per sample. f C57BL/6N mice (8- to 10-week-old males) were treated daily starting at the day of UUO surgery with JQ1 (50 mg/kg) or vehicle, and were sacrificed on day 10 after surgery. g Representative trichrome-stained and Sirius-red stained sections. h Quantification of fibrotic area (masson trichrome +-stained) (n = 7, 5 hpf per sample) and Sirius red+ area (collagen) (n = 7, at least 7 hpf per sample. t-test (two-sided). Data represent the mean ± min, max. Box contains 50% of the data. Scale bars: 100 µm (d), 50 μm (g). Source data are provided as a Source data file.